Duncan Peyton, CEO of 4D Pharma explains the reasons behind their merger and intention to seek a NASDAQ listing
Episode 49, Oct 22, 2020, 03:20 PM
Duncan Peyton, CEO of 4D Pharma explains the reasons behind their merger and intention to seek a NASDAQ listing
Duncan Peyton, Chief Executive Officer of 4D Pharma #DDDD explains the reasons behind their merger and intention to seek a NASDAQ listing.
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.
Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.
#VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast